Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Turns Up Heat On Bid To Acquire CV Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

If Japanese pharma’s gambit fails, it could be in breach of contract with CVT and lose rights to Lexiscan.

You may also be interested in...



Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI

Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market

Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI

Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.

Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI

Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.

Related Content

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel